AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05386108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: 300 mg, 400 mg
Study NCT05386108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 100 mg, 150 mg
Study NCT05624528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: catechol-O-methyl transferase inhibitor
Study NCT05624528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill that contains no medicine
Study NCT04741776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience Enhancement Skills Training
Description: Family therapy
Study NCT04741776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem-Solving Individual Therapy
Description: Individual therapy
Study NCT05203120 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton therapy
Description: All patients will receive proton therapy 67.5Gy/15fx
Study NCT05042089 — intervention group
Intervention type: OTHER
Intervention: No intervention will be applied.
Description: The preoperative imaging of the participants, who were grouped according to the postoperative pathology results, will be examined.
Study NCT05435755 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAESCs treatment
Description: Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.
Study NCT05435755 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo (saline)
Description: 2 times placebo (normal saline) injections as control group
Study NCT04760522 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: WGS Diagnostic: Blood take for genetic diagnostic
Description: Blood sampling, short clinical characterization, WGS based sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics).
Study NCT06383780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GP combined with Tislelizumab
Description: Gemcitabine combined with cisplatin regimen combined with Tislelizumab
Study NCT06383780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPC combined with Tislelizumab
Description: cisplatin, nab-paclitaxel and capecitabine regimen combined with Tislelizumab
Study NCT04647032 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial alternating current stimulation
Description: Transcranial alternating current stimulation (tACS) will be applied across the prefrontal cortex near electrodes coordinates AF3/AF4
Study NCT04647032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation
Description: Transcranial alternating current stimulation (tACS) will be applied across the prefrontal cortex near electrodes coordinates AF3/AF4
Study NCT06451419 — intervention group
Intervention type: OTHER
Intervention: Tests on non motor symptoms
Description: Neurological, neuropsychological and self-administered tests on non motor symptoms, including posturography and speed reaction times.
Study NCT04612946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to Telemedicine LCS Counseling Visit
Description: Patients in the intervention arm will be invited to complete a telemedicine LCS counseling visit, and asked for permission to be referred directly to the LCS navigator to help schedule an appointment. They will also be given the option to directly contact the LCS navigator. Telemedicine counseling visits will be conducted using established clinical procedures for virtual or telephone visits at Penn Medicine. In accordance with reimbursement policies for lung cancer screening, these visits will be conducted by a physician or nurse practitioner within the Lung Cancer Screening Program at Penn Medicine. Counseling visits are covered without co-pay as standalone visits according to USPSTF guidelines and costs will not be covered by the study. LCS is an evidence-based practice and considered standard of care for those who are eligible and desire to be screened. Clinicians retain full control on how to conduct LCS counseling or LDCT in this trial.
Study NCT04612946 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients in the usual care arm will be provided with contact information for the Penn LCS Program and encouraged to discuss LCS with their providers.
Study NCT06265272 — intervention group
Intervention type: DRUG
Intervention: Injection of a gadolinium contrast agen
Description: All patients will be requested to have an injection of a gadolinium contrast agent, which may be either Gadavist (Bayer, Whippany, NJ, USA), Eovist (Bayer, Whippany, NJ, USA), or Dotarem (Guerbet, Princeton, NJ, USA) (ancillary drugs).~* About halfway through the examination, the same intravenous catheter used to inject the radiotracer will be used to inject the MRI contrast agent;~* After being positioned on the PET/MRI table, the nuclear medicine technicians will connect the patient to the MRI-safe power-injector; - The catheter will be flushed before and after injection with 0.9% saline solution;
Study NCT06265272 — intervention group
Intervention type: DRUG
Intervention: Radiotracer Injection
Description: All patients will be requested to have a radiotracer injection of Ga-PSMA (Illucix, Telix Pharmaceuticals). An intravenous catheter will be placed in an arm or hand vein for injection of the Ga-PSMA;~* The catheter will be flushed post-injection with 0.9% saline solution~* The injected dose and the time of injection will be recorded.~* The subjects will be positioned on the scanner table; support devices under the back and/or legs will be used to enable the patient to comfortably maintain his/her position throughout the scan
Study NCT06265272 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: PET, MRI and fused PET/MRI images will be qualitatively assessed in comparison to standard of reference data. For PET, standard of reference will be PET images as obtained by standard PET acquisition mode. Attenuation correction of the PET images will be performed using a 2-point Dixon MRI sequence and a vendor-specific atlas-based attenuation map. 3D scatter correction by single scatter simulation is also performed using the MRI-derived attenuation data. MRI images will be compared to dedicated 3 Tesla MR upper abdominal protocol images acquired at the MGH in patients with liver cirrhosis, including those undergoing imaging follow-up after systemic or local regional therapies. For PET/MRI fused images, the standard of reference will be co-registered and fused PET/MRI images as obtained by standard MRI sequences/reconstructions.
Study NCT05793801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dressing change
Description: The patient circuit corresponds to that of usual care.~Not part of usual patient management:~* The rhythm of PICCline dressing changes, which differed between the two groups.~* The collection of pain on a visual analog scale at each dressing change.
Study NCT05793801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dressing change
Description: The patient circuit corresponds to that of usual care.~Not part of usual patient management:~* The rhythm of PICCline dressing changes, which differed between the two groups.~* The collection of pain on a visual analog scale at each dressing change.
Study NCT05284448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxifylline (Trental SR®)
Description: 400 mg three times daily
Study NCT05349981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Lyric self-replacement procedure
Description: The self-replacement procedure is an experimental procedure in which the Lyric user replaces the Lyric devices independently at every other device replacement, using dedicated candidacy, training, and management procedures, conducted by and at the discretion of his/her hearing care provider (HCP).
Study NCT05154123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: AT-527 + rosuvastatin
Description: * Day 1: A single dose of rosuvastatin will be administered.~* Day 8: A single dose of AT-527 and rosuvastatin will be co-administered.
Study NCT05154123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 + rosuvastatin
Description: * Day 1: A single dose of rosuvastatin will be administered.~* Day 8: A single staggered dose of AT-527 and rosuvastatin will be administered (2 hours later)
Study NCT05306093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutraceutical
Description: Food supplements are consumed during 8 weeks by healthy volunteers
Study NCT05306093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Food supplements are consumed during 8 weeks by healthy volunteers
Study NCT03951064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal balloon
Description: All patients in both groups will have an esophageal balloon catheter inserted by a research investigator. The catheter will be inserted into their nare while upright (head of bed >30 degrees) to a depth slightly more than the estimated distance from the lower sternum to the back of the ear (typically around 60 cm). Gastric positioning will be confirmed with abdominal compression testing and the catheter then retracted 10 - 20cm into the lower esophagus. Placement will be confirmed with the presence of cardiac oscillations on the esophageal probe. The probe will then be secured to the patient's nasal opening using tape.
Study NCT03951064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal balloon
Description: All patients in both groups will have an esophageal balloon catheter inserted by a research investigator. The catheter will be inserted into their nare while upright (head of bed >30 degrees) to a depth slightly more than the estimated distance from the lower sternum to the back of the ear (typically around 60 cm). Gastric positioning will be confirmed with abdominal compression testing and the catheter then retracted 10 - 20cm into the lower esophagus. Placement will be confirmed with the presence of cardiac oscillations on the esophageal probe. The probe will then be secured to the patient's nasal opening using tape.
Study NCT03951064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention Spontaneous Breathing Trial (SBT) and Extubation
Description: Patients in the Intervention group will undergo an SBT regardless of their PEEP level. The PEEP that generates a Ptp of 0 will be considered their optimal PEEP, and this will not be lowered for the SBT. The Intervention Group SBT will consist of a trial of a pressure support of 5 cm H2O and Optimal PEEP.
Study NCT03951064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Spontaneous Breathing Trial and Extubation
Description: Patients in the Control group will undergo an SBT when they reach a PEEP ≤8 cm H2O. This is the current standard of care based on the SBT protocol at UNC Hospitals. SBT and extubation prior to meeting these criteria will be based on primary medical team's discretion and will be recorded for analysis and safety tracking.
Study NCT03951064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention Weaning after Tracheostomy
Description: Based on the use of optimal PEEP in this group, and the experience in the previous study protocol, the investigators will place patients in the Intervention group on Tracheostomy Collar Trial only with a speaking valve. This simulates the normal process of utilizing the upper airway to maintain lung inflation that is performed automatically when a patient does not have an artificial airway.
Study NCT03951064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Weaning after Tracheostomy
Description: The control group will be placed on Tracheostomy Collar Trial with no requirement for speaking valve. They may utilize a speaking valve if tolerated and desired, but there is no requirement as there is in the Intervention group.
Study NCT05256459 — intervention group
Intervention type: OTHER
Intervention: Long term follow-up
Description: No extra intervention.
Study NCT04847284 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy
Description: Intraoperative radiotherapy application immediately following resection of brain metastases.
Study NCT06057662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: personalized comprehensive diabetes support
Description: personalized comprehensive diabetes support
Study NCT05208528 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ES1 group
Description: Participants will intake 2 capsules of 300 mg/capsule with 50 mg of Bifidobacterium longum ES1 (1E09 CFU of probiotic/day, by taking 2 capsules) and 250 mg of maltodextrin.
Study NCT05208528 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HT-ES1 group
Description: Participants will intake 2 capsules of 300 mg/capsule with 50 mg of HT-ES1 (1E09 CFU of probiotic/day, by taking 2 capsules) and 250 mg of maltodextrin.
Study NCT05208528 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Participants will intake 2 capsules of 300 mg/capsule with 300 mg of maltodextrin.
Study NCT05054413 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT05231746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hSTC810
Description: hSTC810 will be administered as an intravenous infusion (IV)
Study NCT05674630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magic Touch drug eluting balloon based strategy
Description: Adult patients with chronic coronary syndrome deemed suitable for percutaneous intervention and significant long de-novo coronary lesion randomized in the experimental arm will receive treatment with drug eluting balloon (Magic Touch®) followed by invasive follow up (FFR and IVUS) at 6 ot 12 months in a randomized fashion.
Study NCT05674630 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent-based strategy
Description: Adult patients with chronic coronary syndrome deemed suitable for percutaneous intervention and significant long de-novo coronary lesion randomized in the control arm will receive treatment with drug-eluting stent followed by invasive follow up (FFR and IVUS) at 6 ot 12 months in a randomized fashion.
Study NCT04953364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART
Description: SMART includes mental and physical wellness, residual/prosthetic limb managements, use of a prosthesis and weekly peer-support calls or video call over Zoom, hosted by University of British Columbia, depends on participant's preference, promoting motivation and establishing goal setting and action planning. The tablet will also allow asynchronous contact with trainers through a secure website.
Study NCT04953364 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive a care booklet and weekly contacts for 6 weeks.
Study NCT05616741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebri biofeedback
Description: Daily use of a mobile application connected with two wireless sensors for measurement of muscle tension, heart rate variability, and peripheral finger temperature, to be used for home-based biofeedback treatment.
Study NCT05616741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebri headache diary
Description: Daily registration of headache and medication with the Cerebri mobile application. This intervention is identical for both study arms.
Study NCT05616741 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cerebri headache diary
Description: Daily registration of headache and medication with the Cerebri mobile application. This intervention is identical for both study arms.
Study NCT05583552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat sodium
Description: Intravenous injection
Study NCT04710732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Enoxaparin 40 mg once-daily before randomization
Description: Once-daily subcutaneous injection of a standard prophylactic dose of Enoxaparin 40 mg according to the set schedule:~* 12 hours before the surgery (if applicable) on a postoperative day -1 (POD -1)~* 6-12 hours after the surgery (key injection 1) on the surgery day (POD 0)~* 12 hours after the previous key injection 1 (key injection 2) on the POD 1~* 24 hours after the previous key injection 2 on the POD 2
Study NCT04710732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Enoxaparin 40 mg once-daily before randomization
Description: Once-daily subcutaneous injection of a standard prophylactic dose of Enoxaparin 40 mg according to the set schedule:~* 12 hours before the surgery (if applicable) on a postoperative day -1 (POD -1)~* 6-12 hours after the surgery (key injection 1) on the surgery day (POD 0)~* 12 hours after the previous key injection 1 (key injection 2) on the POD 1~* 24 hours after the previous key injection 2 on the POD 2
Study NCT04710732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Enoxaparin 40 mg once-daily after randomization
Description: Once-daily subcutaneous injection (every 24 hours) of a standard prophylactic dose of Enoxaparin 40 mg since POD 3 and until discharge
Study NCT04710732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escalated Enoxaparin 30 mg twice-daily after randomization
Description: Twice-daily subcutaneous injection (every 12 hours) of an escalated prophylactic dose of Enoxaparin 30 mg since POD 3 and until discharge
Study NCT04710732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anti-embolic elastic compression stockings
Description: Applied before or just after the surgery and used around the clock until discharge
Study NCT04710732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-embolic elastic compression stockings
Description: Applied before or just after the surgery and used around the clock until discharge
Study NCT04710732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Thrombodynamic test (TD)
Description: Blood sampling for TD:~* 12 hours after key injection 1 (TD-12) on the POD 1~* 24 hours after key injection 2 (TD-24) on the POD 2~* 24 hours after each daily injection on the POD 4 (TD-4) and POD 5 (TD-5)
Study NCT04710732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thrombodynamic test (TD)
Description: Blood sampling for TD:~* 12 hours after key injection 1 (TD-12) on the POD 1~* 24 hours after key injection 2 (TD-24) on the POD 2~* 24 hours after each daily injection on the POD 4 (TD-4) and POD 5 (TD-5)
Study NCT06479096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brush / Espresso Mild Prototype
Description: Subjects will brush and rinse with their assigned mouthwash twice daily.
Study NCT06479096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brush / Espresso Intense Prototype
Description: Subjects will brush and rinse with their assigned mouthwash twice daily.
Study NCT06479096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brush / Fresh Breath Oral Rinse
Description: Subjects will brush and rinse with their assigned mouthwash twice daily.
Study NCT06479096 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Brush / Hydroalcohol
Description: Subjects will brush and rinse with their assigned mouthwash twice daily.
Study NCT05109117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP Unscented
Description: Sunscreen lip balm.
Study NCT05035368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ladarixin
Description: Ladarixin will be administered orally at the dose of 400 mg twice a day at about 12-hour interval (morning and evening).
Study NCT05035368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered with the same schedule of Ladarixin.
Study NCT05962983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small Steps for Big Changes Program
Description: Participants will be asked to attend six one on one sessions providing diet and exercise counselling each lasting 20-30 minutes over the course of six weeks. The nutrition counselling will introduce participants to a healthy dietary changes for reducing added sugar intake and refined/processed carbohydrate intake as well as increasing vegetable consumption. After counselling sessions, participants will complete their chosen form of aerobic exercise: 1) traditional continuous exercise that involves exercising at a constant pace for 20-30 minutes (moderate-intensity continuous training, MICT); or 2) interval exercise that involves alternating between 30 seconds and 1-minute of brisk exercise and 1-minute of easy exercise for \~15 min (high-intensity interval training, HIIT). Both exercise forms could be completed on treadmill, elliptical or stationary bike. In total, each session will last approximately one hour.
Study NCT05333029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stromal cells (MSCs)
Description: Treatment dose 2 x10\^6 cells/kg (+/- 20%)
Study NCT05333029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP)
Description: Blood is collected through an intravenous (IV) line which is connected to an apheresis machine.The machine adds a chemical that makes the white blood cells sensitive to light. Then the machine shines a light on the cells and then returns the blood to the participant
Study NCT06288659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraventricular intracranial pressure monitoring
Description: The postoperative management of ICP is guided by quantifiable Intraventricular ICP parameters. The remaining treatments are consistent with those in the control group.
Study NCT05147792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLAAS
Description: CLAAS
Study NCT05147792 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder
Description: WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder